Drug-induced hepatotoxicity

Pharmaceutical preparations, but also herbal products and dietary supplements, are emerging contributors to severe forms of liver disease, with hepatotoxicity ranking as the most frequent cause for acute liver failure. Although acetaminophen intoxication is still the reason for many severe cases of druginduced liver injury, the bulk of hepatic reactions to drugs are idiosyncratic. Indeed, the rarity of this serious adverse event prevents its detection in clinical trials. Therefore, in order to collect reliable data, prospective post-marketing studies are needed, especially with commonly used drugs that have been shown to be associated with drug-induced liver injury. Recently, different databases have described acetaminophen, antibiotics, nonsteroidal anti-inflammatory drugs, and anticonvulsants as being associated with drug-induced liver injury. Clinical presentations of drug-induced liver injury include predominantly a hepatocellular type of damage, yet cholestatic and mixed types are also common, the determinants of the type of damage induced by a given drug being poorly understood. Recent analysis of pooled data has underlined the influence of older age in the cholestatic/mixed expression of the liver injury, as well as the independent association of female gender, older age, aspartate aminotransferase levels/hepatocellular type of damage and high bilirubin levels with the risk of fulminant liver failure/death. In the long-term (proving the patient survives to the initial episode) cholestatic mixed type of damage is more prone to become chronic, while in the hepatocellular pattern the severity is greater, with further likelihood of evolution to cirrhosis. Cardiovascular and central nervous system drugs have been found to be the main groups leading to chronic liver damage. The diagnosis of hepatotoxicity remains a difficult task because of the lack of reliable markers for use in general clinical practice. To incriminate any given drug in an episode of liver dysfunction is a step-by-step process that requires a high degree of suspicion, compatible chronology, awareness of the drug’s hepatotoxic potential, the exclusion of alternative causes of liver damage, and the ability to detect the presence of subtle data that favors a toxic etiology. This process is time-consuming and the final result is frequently inaccurate. Diagnostic algorithms may add consistency to the diagnostic process by translating the suspicion into a quantitative score. Such scales are useful since they provide,

[1]  R. Victorino,et al.  Development and validation of a clinical scale for the diagnosis of drug‐induced hepatitis , 1997, Hepatology.

[2]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.

[3]  H. Zimmerman,et al.  Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver , 1978 .

[4]  E. Björnsson,et al.  Severe Jaundice in Sweden in the New Millennium: Causes, Investigations, Treatment and Prognosis , 2003, Scandinavian journal of gastroenterology.

[5]  B. Strom,et al.  Acute Liver Disease Associated with Erythromycins, Sulfonamides, and Tetracyclines , 1993, Annals of Internal Medicine.

[6]  G. Farrell,et al.  Drug induced liver disease , 2000 .

[7]  A. Flahault,et al.  Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. , 1993, Journal of clinical epidemiology.

[8]  M I Lucena,et al.  Trovafloxacin-induced acute hepatitis. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Whitehead,et al.  A prospective study of the causes of notably raised aspartate aminotransferase of liver origin , 1999, Gut.

[10]  R. Andrade,et al.  Causality assessment in drug-induced hepatotoxicity , 2004, Expert opinion on drug safety.

[11]  R. Andrade,et al.  Comparison of two clinical scales for causality assessment in hepatotoxicity , 2001, Hepatology.

[12]  M. Lucena,et al.  Bentazepam-associated chronic liver disease , 1994, The Lancet.

[13]  William M. Lee,et al.  Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions , 2005, Toxicologic pathology.

[14]  K. Tomecki Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines: Carson JL, Strom BL, Duff A, et al. Ann Intern Med 1993;119:576-83 , 1995 .

[15]  J P Cambus,et al.  Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. , 2001, British journal of clinical pharmacology.

[16]  M. Rawlins,et al.  Accuracy of hepatic adverse drug reaction reporting in one English health region , 1999, BMJ.

[17]  Acute liver failure in the United States , 2003 .

[18]  William M. Lee,et al.  Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States , 2002, Annals of Internal Medicine.

[19]  N. Kaplowitz Causality assessment versus guilt‐by‐association in drug hepatotoxicity , 2001, Hepatology.

[20]  L. Bianchi,et al.  Liver biopsy in elevated liver functions tests? An old question revisited. , 2001, Journal of hepatology.

[21]  P. Hillon,et al.  Incidence of drug‐induced hepatic injuries: A French population‐based study , 2002, Hepatology.

[22]  J. Hoofnagle,et al.  Drug‐induced liver injury network (DILIN) , 2004, Hepatology.

[23]  R. Andrade,et al.  Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. , 1999, Journal of hepatology.

[24]  M W Whitehead,et al.  The causes of obvious jaundice in South West Wales: perceptions versus reality , 2001, Gut.

[25]  C. Day,et al.  The natural history of histologically proved drug induced liver disease , 1999, Gut.

[26]  R. Andrade,et al.  Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity. , 2000, Digestive diseases and sciences.

[27]  H. Jick,et al.  A Review of Epidemiologic Research on Drug‐Induced Acute Liver Injury Using the General Practice Research Data Base in the United Kingdom , 1997, Pharmacotherapy.

[28]  M. Rawlins,et al.  Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. , 2000, Journal of hepatology.

[29]  T. Hutchinson,et al.  Assessing methods for causality assessment of suspected adverse drug reactions. , 1989, Journal of clinical epidemiology.

[30]  S. Gutthann,et al.  The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. , 1993 .

[31]  G. Minuk,et al.  Clinical hepatology: Profile of an urban, hospital‐based practic , 1996, Hepatology.

[32]  M. Duh,et al.  Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts , 1999, Pharmacoepidemiology and drug safety.

[33]  F. Berr,et al.  Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS). , 2002, Journal of hepatology.

[34]  C. Bénichou Criteria of drug-induced liver disorders. Report of an international consensus meeting. , 1990, Journal of hepatology.

[35]  T. Almdal,et al.  Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: Analysis of hospitalization registry data , 1991, Hepatology.

[36]  D. Larrey Drug-induced liver diseases. , 2000, Journal of hepatology.

[37]  A. Walker,et al.  The role of non-steroidal anti-inflammatory drugs in acute liver injury. , 1992, BMJ.